MedTrace Logo

Pregabalin (Lyrica) for the Treatment of Essential Tremor

NCT00584376 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2012-06-18

No results posted yet for this study

Summary

This will be a multi-site, prospective, double-blind, randomized, placebo-controlled, crossover trial conducted over 6 months to assess the effectiveness and safety of PGB to treat symptoms of ET.

Conditions

Interventions

DRUG

Pregabalin

Gradually titrated dose ranging from 75mg po bid to 225mg po bid.

DRUG

Placebo

Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of South Florida

    lead OTHER

Principal Investigators

  • Theresa A Zesiewicz, MD · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584376 on ClinicalTrials.gov